This presentation may include forward-looking statements. The words "expect," "reiterating," "durable," "continue," "shifting," "expand," "believe," "continued," "assumes," "continuing," "rising," "well positioned," "strong," "increase," "benefitting," "raising," "creating," "expected," and similar expressions (or their negative) identify certain of these forward-looking statements. These forward-looking statements are statements regarding the Company's intentions, beliefs or current expectations concerning ...

Stevanato Group S.p.A. (NYSE:STVN) Q2 2023 Earnings Conference Call July 28, 2023 8:30 AM ET Lisa Miles - Senior Vice President, Investor Relations Franco Stevanato - Executive Chairman Franco Moro - Chief Executive Officer Marco Dal Lago - Chief Financial Officer Patrick Donnelly - Citi Paul Knight - KeyBanc David Windley - Jefferies Derik de Bruin - Bank of America Drew Ranieri - Morgan Stanley Matt Larew - William Blair Good afternoon. This is a Chorus Call conference operator. Welcome and thank you for ...

We are on track with our plans. And so we expect to have a commercial sales from Latina in the last quarter of this year. And validation activity in Fishers, Indiana under completion in the last part of the year to have a first revenue generation in the first half of '24. In China, we remain a strategic target for us in terms of market, and we decided to pause the investment for a while, and we still expect to take Tim Daley Dave Windley Thank you for the question. In the second part of the year, we expect ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of ...

Stevanato Group S.p.A. (NYSE:STVN) Q4 2022 Earnings Conference Call March 2, 2023 8:30 AM ET Company Participants Lisa Miles - SVP Investor Relations Franco Stevanato - Executive Chairman Franco Moro - Chief Executive Officer Marco Dal Lago - Chief Financial Officer Conference Call Participants Paul Knight - KeyBanc Capital Markets Patrick Donnelly - Citi Derik De Bruin - Bank of America Tim Daley - Wells Fargo John Sourbeer - UBS David Windley - Jefferies Madeline Mollman - William Blair Drew Ranieri - Mor ...

Exhibit 99.1 For the fourth quarter of 2022, gross profit margin increased 290 basis points to 34.3% driven by higher revenue, the mix shift to high value solutions, better leverage of fixed costs, and the recovery of inflationary costs, while operating profit margin of 21.6% included a benefit of €3.0 million related to a joint development project. Full Year 2022 Results Revenue for fiscal 2022 increased 17% to €983.7 million (approximately 13% on a constant currency basis), compared with the same period l ...

Stevanato Group Q4 and Full Year 2022 Financial Results March 2nd, 2023 Safe Harbor Statement Forward-Looking Statements This presentation may include forward-looking statements. The words "expect," "growth", "deliver" "drive," "create," "accelerating," "sustained," "believe," "building," "future," "well positioned," "continues," "remain," "estimate," and similar expressions (or their negative) identify certain of these forward-looking statements. These forward-looking statements are statements regarding th ...

Financial Data and Key Metrics Changes - For Q3 2022, revenue increased by 14% to €245.3 million compared to the previous year, driven by growth in the Biopharmaceutical and Diagnostic Solutions segment and favorable currency translation [24] - Adjusted EBITDA margin was reported at 26.8% [26] - Gross profit margin increased by 210 basis points to 31.6%, primarily due to a strategic shift towards high-value solutions [25] - Net profit for Q3 2022 was €36.3 million, or €0.14 diluted earnings per share [26] Business Line Data and Key Metrics Changes - Revenue from the Biopharmaceutical and Diagnostic Solutions segment increased by 20% to €207.1 million, with high-value solutions growing by 54% to €74.4 million [27] - The Engineering segment saw a revenue decrease of 9% to €38.2 million, attributed to project timing [29] Market Data and Key Metrics Changes - New order intake for Q3 totaled €247 million, with a year-over-year decrease due to a drop in COVID-19 orders; excluding COVID, new order intake increased by approximately 6% [14] - Committed backlog increased by 21% to just over €1 billion [14] Company Strategy and Development Direction - The company is focused on advancing global capacity expansion, growing the mix of high-value solutions, investing in R&D, and building a multi-year pipeline of new opportunities [36] - The introduction of the EZ-Fill Smart platform aims to enhance productivity and reduce contamination risks, aligning with the company's long-term strategy of providing integrated solutions [15][18] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about demand trends, particularly in the context of the growing pipeline for new treatments, with approximately 60% tied to injectable delivery [8] - The company is proactively managing inflationary pressures and supply chain complexities, with expectations of continued strong demand for high-value solutions [13][14] Other Important Information - The company has a strong balance sheet with a positive net financial position of €49.6 million and cash and cash equivalents of €259.9 million as of September 30 [31] - Capital expenditures for Q3 were €71.1 million, reflecting ongoing investments in strategic global expansion plans [31] Q&A Session Summary Question: Update on COVID revenue contribution - Management confirmed that COVID-related revenue is still expected to be around 10% for the year [43] Question: Demand for non-COVID products - Management indicated that demand remains strong, with an increase in order intake year-over-year, particularly for high-value solutions [46] Question: EZ-Fill Smart collaboration structure - Revenue from EZ-Fill products will be independent, with potential shared licensing fees if technology is licensed to third parties [53] Question: Margin dynamics with high-value solutions - Management stated that margins for COVID and non-COVID products are similar, and they are successfully replacing COVID orders with strong demand for other therapeutic areas [65] Question: Capacity expansion timelines - Construction of the Indiana facility is on track, with no anticipated delays in revenue recognition [72] Question: Pricing and inflationary cost pushback - Management noted that they have passed on costs to customers but are focused on long-term relationships rather than immediate gains [74]

Stevanato Group S.p.A. (NYSE:STVN) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Lisa Miles - Investor Relations Franco Stevanato - Chairman Franco Moro - Chief Executive Officer Marco Dal Lago - Chief Financial Officer Conference Call Participants Paul Knight - KeyBanc Justin Lin - William Blair Derik De Bruin - Bank of America Patrick Donnelly - Citi Steven Couche - Jefferies John Sourbeer - UBS Operator Good afternoon. This is the Chorus Call Conference operator. Welcome ...

Second Quarter 2022 Financial Results August 4, 2022 Safe-Harbor Statement Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current views of Stevanato Group S.p.A. ("we", "our", "us", "Stevanato Group" or the "Company"). These forward-looking statements include, or may include, words such as "plan", "advancing", "emerging", "opportunities", "increasing", "trends", "advancement" ...